New eczema drug enters first human tests
NCT ID NCT06553209
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 24 times
Summary
This early-stage study tested a new medicine called CM512 in 110 healthy volunteers and people with moderate to severe eczema (atopic dermatitis). The main goal was to check if the drug is safe and how the body handles it. Participants received either the drug or a placebo, and researchers tracked any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Conditions
Explore the condition pages connected to this study.